Eupraxia Pharmaceuticals, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- James A. Helliwell
- Full Time Employees
- 49
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 2067 Cadboro Bay Road Victoria BC Canada V8R 5G4
- IPO Date
- Mar 9, 2021
- Website
- eupraxiapharma.com
- Similar Companies
- Business
- Eupraxia Pharmaceuticals Inc. (TSX/NASDAQ: EPRX) is a clinical-stage biotechnology company focused on developing locally delivered, extended-release products that address high unmet medical needs in inflammatory, gastrointestinal, musculoskeletal, oncology, and pain disorders using its proprietary Diffusphere polymer-based micro-sphere technology for targeted drug delivery; core product candidates include EP-104GI, administered via esophageal wall injection for eosinophilic esophagitis (EoE) in the ongoing Phase 1b/2a RESOLVE trial and Phase 2b placebo-controlled study with topline data expected in H2 2026, and EP-104IAR for knee osteoarthritis pain following completion of the Phase IIb SPRINGBOARD trial, alongside an earlier-stage pipeline for additional inflammatory joint indications and other long-acting formulations. Founded in 2011 and headquartered in Victoria, British Columbia, Canada, with additional facilities in Vancouver, the company employs 33 people and operates primarily in North America while pursuing global markets for its therapies in multibillion-dollar indications such as EoE, estimated to affect over one million US patients by 2029, and joint pain where current treatments underperform on efficacy, safety, duration, and convenience. Recent developments include positive 12-month data from the highest-dose RESOLVE cohort showing two-thirds of patients in clinical remission and sustained tissue health improvements across cohorts, first patient dosing in the Phase 2b RESOLVE portion announced August 2025, and the closing of an upsized US$80.5 million public offering in September 2025 with full underwriter option exercise, extending cash runway into Q1 2028 to fund pipeline advancement, preclinical/clinical studies, regulatory submissions, manufacturing scale-up, and business development.
Company News
Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day
Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences
Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients
Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results
Wall Street Analysts See a 145.35% Upside in Eupraxia Pharmaceuticals Inc. (EPRX): Can the Stock Really Move This High?
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Consensus Rating of “Moderate Buy” by Brokerages
Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth
Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization
Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders
Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results
Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week
Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)
Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer
Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting
New Strong Sell Stocks for April 2nd
Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst